In order to focus its resources on its lead antibody-drug conjugate (ADC) and an array of Big Pharma partnerships, CytomX is considering the future of the Amgen ... $300 million off the value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback